{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:33:16Z","timestamp":1791473596876,"version":"4.3.4"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    On the current psychopharmacological panorama, the variety of substances able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic episodes are classified according to the major category of symptoms: positive, negative, or cognitive psychotic episodes. On one hand, the abuse of methamphetamines, cannabis, and cocaine plays a big role in increasing the incidence of episodes resembling a psychotic disorder. On the other hand, the progress in terms of pharmacodynamics knowledge has led to the synthesis of new drugs, such as cannabinoids and cathinone's, which have rapidly entered into the common pool of abusers' habits. Regarding these newly synthesized substances of abuse, further clinical studies are needed to understand their psychogenic properties. The topic of this review is complicated due to the frequent abuse of psychotomimetic drugs by patients affected by psychotic disorders, a fact that makes it extremely difficult to distinguish between an induced psychosis and a re-exacerbation of a previously diagnosed disorder.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The present narrative review summarizes results from clinical studies, thus investigating the psychotogenic properties of abused substances and the psychotic symptoms they can give rise to. It also discusses the association between substance abuse and psychosis, especially with regards to the differential diagnosis between a primary vs. a substance-induced psychotic disorder.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Findings:<\/jats:bold>\n                    Our findings support the theory that psychosis due to substance abuse is commonly observed in clinical practice. The propensity to develop psychosis seems to be a function of the severity of use and addiction. Of note, from a phenomenological point of view, it is possible to identify some elements that may help clinicians involved in differential diagnoses between primary and substance-induced psychoses. There remains a striking paucity of information on the outcomes, treatments, and best practices of substance-induced psychotic episodes.\n                  <\/jats:p>","DOI":"10.3389\/fpsyt.2021.694863","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T03:12:18Z","timestamp":1640229138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":136,"title":["Substance-Induced Psychoses: An Updated Literature Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Alessio","family":"Fiorentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Cant\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Crisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/dar.12280","article-title":"Associations between psychotic symptoms and substance use in young offenders","volume":"34","author":"Degenhardt","year":"2015","journal-title":"Drug Alcohol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/1874473711104040228","article-title":"Substance-induced psychoses: A critical review of the literature","volume":"4","author":"Fiorentini","year":"2011","journal-title":"Curr Drug Abuse Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/15622975.2016.1139747","article-title":"Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review","volume":"18","author":"Cooper","year":"2017","journal-title":"World J Biol Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2017.06.018","article-title":"Cannabis-associated psychosis: Neural substrate and clinical impact","volume":"15","author":"Murray","year":"2017","journal-title":"Neuropharmacology."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2019.10.005","article-title":"Diagnostic stability in substance-induced psychosis","author":"Inchausti","year":"2020","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","year":"2013","journal-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5, Fifth edit","DOI":"10.1176\/appi.books.9780890425596"},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/brainsci8120221","article-title":"Recent changes in drug abuse scenarios: The new\/novel psychoactive substances (NPS) phenomenon","volume":"8","author":"Schifano","year":"2018","journal-title":"Brain Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajp.2017.04.014","article-title":"Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up","volume":"29","author":"Mauri","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.schres.2017.11.001","article-title":"Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review","volume":"197","author":"Wilson","year":"2018","journal-title":"Schizophr Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1176\/appi.ajp.2018.17121395","article-title":"Substance-Induced psychosis: An indicator of development of primary psychosis?","volume":"175","author":"Ghose","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1192\/bjp.bp.105.015784","article-title":"Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis","volume":"190","author":"Caton","year":"2007","journal-title":"Br J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","article-title":"Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis","volume":"175","author":"Starzer","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/jamapsychiatry.2020.0339","article-title":"Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis?","volume":"77","author":"Murray","year":"2020","journal-title":"JAMA Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2012.11.020","article-title":"Psychoactive \u201cbath salts\u201d: Not so soothing","volume":"698","author":"Baumann","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/bph.12061","article-title":"Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter","volume":"168","author":"Cameron","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.toxlet.2012.03.009","article-title":"Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as \u201cbath salts\u201d or \u201cplant food.\u201d Toxicol","volume":"211","author":"Coppola","year":"2012","journal-title":"Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2013.05.024","article-title":"Mephedrone: Public health risk, mechanisms of action, behavioral effects","volume":"714","author":"Dybdal-Hargreaves","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.forsciint.2013.04.015","article-title":"Designer cathinones-An emerging class of novel recreational drugs","volume":"231","author":"Zawilska","year":"2013","journal-title":"Forensic Sci Int."},{"key":"B20","year":"2020","journal-title":"How Does Cocaine Produce Its Effects?"},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0014-2999(02)02867-4","article-title":"Cocaine inhibits 5-HT3 receptor function in neurons from transgenic mice overexpressing the receptor","volume":"459","author":"Carta","year":"2003","journal-title":"Eur J Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1365-2125.2010.03629.x","article-title":"Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias","volume":"69","author":"O'Leary","year":"2010","journal-title":"Br J Clin Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.eurpsy.2011.06.012","article-title":"Risk factors for cocaine-induced psychosis in cocaine-dependent patients","volume":"28","author":"Roncero","year":"2013","journal-title":"Eur Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.psychres.2012.04.008","article-title":"Cocaine-induced psychotic symptoms in French cocaine addicts","volume":"200","author":"Vorspan","year":"2012","journal-title":"Psychiatry Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1146\/annurev.pa.33.040193.003231","article-title":"Amphetamine: Effects on catecholamine systems and behavior","volume":"32","author":"Seiden","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fpsyt.2018.00489","article-title":"Epidemiological characteristics and risk factors of methamphetamine-associated psychotic symptoms","volume":"9","author":"Su","year":"2018","journal-title":"Front Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fpsyt.2018.00551","article-title":"A research of methamphetamine induced psychosis in 1,430 individuals with methamphetamine use disorder: Clinical features and possible risk factors","volume":"9","author":"Gan","year":"2018","journal-title":"Front Psychiatry."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-75124-5","volume-title":"Hallucinations in Psychoses and Affective Disorders, A Clinical and Biological Approach","author":"Brambilla","year":"2018"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1021\/acschemneuro.8b00155","article-title":"Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine (MDMA)","volume":"9","author":"Dunlap","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"B30","year":"2019","journal-title":"World drug report 2019 Booklet 1, Executive Summary"},{"key":"B31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/FBP.0000000000000426","article-title":"The acute effects of cannabis on human executive function","volume":"29","author":"Oomen","year":"2018","journal-title":"Behav Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous 9- tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","article-title":"Keep off the grass? Cannabis, cognition and addiction","volume":"17","author":"Curran","year":"2016","journal-title":"Nat Rev Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ajp.2017.10.003","article-title":"Cannabis induced psychosis and subsequent psychiatric disorders","volume":"30","author":"Shah","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-018-0191-x","article-title":"Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function","volume":"8","author":"Morgan","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1177\/0269881112446534","article-title":"Does olanzapine inhibit the psychomimetic effects of \u03b49- tetrahydrocannabinol?","volume":"26","author":"Kleinloog","year":"2012","journal-title":"J Psychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/npp.2010.222","article-title":"Disruption of frontal theta coherence by \u03b4 9-tetrahydrocannabinol is associated with positive psychotic symptoms","volume":"36","author":"Morrison","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci Mar."},{"key":"B40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archgenpsychiatry.2009.17","article-title":"Modulation of mediotemporal and ventrostriatal function in humans by A9-tetrahydrocannabinol a neural basis for the effects of cannabis sativa on learning and psychosis","volume":"662","author":"Bhattacharyya","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1017\/S1461145711001581","article-title":"Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes","volume":"15","author":"O'Tuathaigh","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1177\/0269881110382465","article-title":"Does intravenous \u03949-tetrahydrocannabinol increase dopamine release? A SPET study","volume":"25","author":"Barkus","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/npp.2015.58","article-title":"GABA deficits enhance the psychotomimetic effects of \u0394 9-THC","volume":"40","author":"Radhakrishnan","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1017\/S0033291711002078","article-title":"Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort","volume":"42","author":"Manrique-Garcia","year":"2012","journal-title":"Psychol Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2014.04.023","article-title":"Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences","volume":"157","author":"van Gastel","year":"2014","journal-title":"Schizophr Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1017\/S0033291714000117","article-title":"Cannabis use and transition to psychosis in people at ultra-high risk","volume":"44","author":"Valmaggia","year":"2014","journal-title":"Psychol Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fpsyt.2019.00514","article-title":"Longitudinal alterations in prefrontal resting brain connectivity in non-treatment-seeking young adults with cannabis use disorder","volume":"10","author":"Camchong","year":"2019","journal-title":"Front Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/jcph.827","article-title":"The pharmacologic and clinical effects of illicit synthetic cannabinoids","volume":"57","author":"White","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.drugpo.2014.02.001","article-title":"Drug Policy Governance in the UK: Lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act","volume":"25","author":"Monaghan","year":"2014","journal-title":"Int J Drug Policy."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1021\/ac900564u","article-title":"Investigating a not-so-natural high","volume":"81","author":"Piggee","year":"2009","journal-title":"Anal. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FBP.0000000000000323","article-title":"Synthetic cannabinoids: The hidden side of Spice drugs","volume":"28","author":"Pintori","year":"2017","journal-title":"Behav Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin Toxicol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.psym.2011.01.004","article-title":"Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists","volume":"52","author":"Benford","year":"2011","journal-title":"Psychosomatics."},{"key":"B54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08897077.2012.677754","article-title":"Synthetic cannabinoid overdose in a 20-year-old male US soldier","volume":"34","author":"Berry-Cab\u00e1n","year":"2013","journal-title":"Subst Abus."},{"key":"B55","first-page":"18","article-title":"Hospitalisation associated with use of the synthetic cannabinoid K2","volume":"28","author":"Glue","year":"2013","journal-title":"N Z Med J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"718","DOI":"10.7205\/MILMED-D-10-00356","article-title":"Spice: a legal marijuana equivalent","volume":"176","author":"Johnson","year":"2011","journal-title":"Mil Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/cap.2012.0004","article-title":"Synthetic cannabinoid-induced psychosis: Two adolescent cases","volume":"22","author":"Oluwabusi","year":"2012","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1521-0391.2012.00222.x","article-title":"Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient","volume":"21","author":"Peglow","year":"2012","journal-title":"Am J Addict."},{"key":"B59","doi-asserted-by":"publisher","first-page":"7257489","DOI":"10.1155\/2016\/7257489","article-title":"First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone","volume":"2016","author":"Roberto","year":"2016","journal-title":"Case Rep Psychiatry"},{"key":"B60","first-page":"38","article-title":"Synthetic marijuana use and development of catatonia in a 17-year-old male","volume":"97","author":"Smith","year":"2014","journal-title":"Minn Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2011.04.022","article-title":"Persistent psychosis following the use of Spice","volume":"130","author":"Van Der Veer","year":"2011","journal-title":"Schizophr Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PEC.0b013e3181e4f416","article-title":"A teenager with agitation: Higher than she should have climbed","volume":"26","author":"Vearrier","year":"2010","journal-title":"Pediatr Emerg Care."},{"key":"B63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.forsciint.2010.04.003","article-title":"Detection of JWH-018 metabolites in smoking mixture post-administration urine","volume":"200","author":"Sobolevsky","year":"2010","journal-title":"Forensic Sci Int."},{"key":"B64","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3928\/01477447-20140401-62","article-title":"Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations","volume":"37","author":"Meijer","year":"2014","journal-title":"Orthopedics."},{"key":"B65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ajad.12318","article-title":"Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis","volume":"25","author":"Khan","year":"2016","journal-title":"Am J Addict"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1515\/ijamh-2013-0505","article-title":"Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness","volume":"40","author":"Rahmani","year":"2014","journal-title":"Int J Adolesc Med Health."},{"key":"B67","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.drugalcdep.2011.01.012","article-title":"Synthetic cannabinoid JWH-018 and psychosis: An explorative study","volume":"117","author":"Every-Palmer","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"B68","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/15504263.2014.929364","article-title":"Use of synthetic cannabinoids in patients with psychotic disorders: Case series","volume":"10","author":"Celofiga","year":"2014","journal-title":"J Dual Diagn."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1360-0443.2010.03119.x","article-title":"Warning: Legal synthetic cannabinoid-receptor agonists such as JWH-018 May precipitate psychosis in vulnerable individuals","volume":"105","author":"Every-Palmer","year":"2010","journal-title":"Addiction."},{"key":"B70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.schres.2009.12.001","article-title":"The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes","volume":"118","author":"M\u00fcller","year":"2010","journal-title":"Schizophr Res."},{"key":"B71","unstructured":"2015"},{"key":"B72","first-page":"284","article-title":"Sur un homologue de l'ephedrine","volume":"45","author":"Saem de Burnaga","year":"1929","journal-title":"Bull Soci\u00e9t\u00e9 Chim Fr."},{"key":"B73","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/dta.313","article-title":"Cathinone derivatives: A review of their chemistry, pharmacology and toxicology","volume":"3","author":"Kelly","year":"2011","journal-title":"Drug Test Anal."},{"key":"B74","article-title":"Mephedrone: An update on current knowledge","author":"Sumnall","year":"2009","journal-title":"NorthWest Public Heal Obs."},{"key":"B75","year":"2014","journal-title":"European Drug Report 2014: Trends and developments, Report"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1476-5381.2011.01499.x","article-title":"Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats","volume":"164","author":"Kehr","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The toxicology of bath salts: a review of synthetic cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J Med Toxicol."},{"key":"B78","year":"2011","journal-title":"Risk Assessment Report of a New Psychoactive Substance: 4-Methylmethcathinone (mephedrone)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/emj.2010.096636","article-title":"Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service","volume":"26","author":"James","year":"2011","journal-title":"Emerg Med J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cber.188702001142","article-title":"Ueber einige derivate der phenylmethacryls\u00e4ure und der phenylisobutters\u00e4ure","volume":"20","author":"Gaedcke","year":"1887","journal-title":"Berichte der Dtsch Chem Gesellschaft"},{"key":"B81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2011.01.013","article-title":"Incidence of psychopathology in a cohort of young heroin and\/or cocaine users","volume":"41","author":"Herrero","year":"2011","journal-title":"J Subst Abuse Treat."},{"key":"B82","first-page":"623","article-title":"Cocaine induced psychotic disorders: A review","volume":"65","author":"Karila","year":"2010","journal-title":"Rev Med Liege."},{"key":"B83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1037\/e324222004-013","article-title":"Cocaine-induced psychosis","volume":"25","author":"Brady","year":"1991","journal-title":"J Clin Psychiatry."},{"key":"B84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/08897077.2012.691446","article-title":"Psychotic symptoms of cocaine self-injectors in a harm reduction program","volume":"34","author":"Roncero","year":"2013","journal-title":"Subst Abus."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2014.01.026","article-title":"Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients","volume":"2016","author":"Roncero","year":"2014","journal-title":"Psychiatry Res."},{"key":"B86","first-page":"187","article-title":"Prevalence and risk factors of psychotic symptoms in cocaine-dependent patients","volume":"40","author":"Roncero","year":"2012","journal-title":"Actas Esp Psiquiatr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2005.03.019","article-title":"Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP)","volume":"80","author":"Cubells","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"B88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/10550490701861201","article-title":"Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants","volume":"17","author":"Mahoney","year":"2008","journal-title":"Am J Addict."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1176\/ajp.148.12.1708","article-title":"Cocaine-induced paranoia and psychosis proneness","volume":"148","author":"Satel","year":"1991","journal-title":"Am J Psychiatry."},{"key":"B90","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/10550490701525723","article-title":"Comorbid psychiatric diagnoses and their association with cocaine-induced psychosis in cocaine-dependent subjects","volume":"16","author":"Tang","year":"2007","journal-title":"Am J Addict."},{"key":"B91","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1521-0391.2011.00181.x","article-title":"Prospective assessment of transient cocaine-induced psychotic symptoms in a clinical setting","volume":"20","author":"Vorspan","year":"2011","journal-title":"Am J Addict."},{"key":"B92","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0893-133X(96)00164-9","article-title":"Selective sensitisation to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability?","volume":"16","author":"Bartlett","year":"1997","journal-title":"Neuropsychopharmacology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jpsychires.2005.05.001","article-title":"Risk factors for experiencing psychosis during cocaine use: A preliminary report","volume":"40","author":"Floyd","year":"2006","journal-title":"J Psychiatr Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugalcdep.2005.12.002","article-title":"Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs","volume":"84","author":"Kalayasiri","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"B95","first-page":"115","article-title":"Characteristics of freebase cocaine psychosis","volume":"61","author":"Manschreck","year":"1988","journal-title":"Yale J Biol Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/10550887.2013.824330","article-title":"Cocaine-induced psychosis and impulsivity in cocaine-dependent patients","volume":"32","author":"Roncero","year":"2013","journal-title":"J Addict Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.npp.1380106","article-title":"Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia","volume":"11","author":"Gelernter","year":"1994","journal-title":"Neuropsychopharmacology."},{"key":"B98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/gbb.12013","article-title":"Association study of 37 genes related to serotonin and dopamine neurotransmission and neurotrophic factors in cocaine dependence","volume":"12","author":"Fern\u00e0ndez-Castillo","year":"2013","journal-title":"Genes Brain Behav."},{"key":"B99","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/15622975.2010.551406","article-title":"Candidate pathway association study in cocaine dependence: The control of neurotransmitter release","volume":"13","author":"Fernndez-Castillo","year":"2012","journal-title":"World J Biol Psychiatry."},{"key":"B100","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.ypg.0000242198.59020.ca","article-title":"Human clock, PER1 and PER2 polymorphisms: Lack of association with cocaine dependence susceptibility and cocaine-induced paranoia","volume":"16","author":"Malison","year":"2006","journal-title":"Psychiatr Genet."},{"key":"B101","year":"2019","journal-title":"World Drug Report"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-016-1002-7","article-title":"Psychosis associated with acute recreational drug toxicity: A European case series","volume":"16","author":"Vallersnes","year":"2016","journal-title":"BMC Psychiatry."},{"key":"B103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.psychres.2018.05.033","article-title":"The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis","volume":"268","author":"Lecomte","year":"2018","journal-title":"Psychiatry Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fnhum.2014.00537","article-title":"The neurobiology of methamphetamine induced psychosis","volume":"8","author":"Hsieh","year":"2014","journal-title":"Front Hum Neurosci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0004867417748750","article-title":"A systematic review of risk factors for methamphetamine-associated psychosis","volume":"52","author":"Arunogiri","year":"2018","journal-title":"Aust N Z J Psychiatry."},{"key":"B106","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/10550887.2019.1661752","article-title":"Factors affecting the occurrence of psychotic symptoms in chronic methamphetamine users","volume":"37","author":"Nie","year":"2018","journal-title":"J Addict Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2019-032711","article-title":"Risks of psychosis in methamphetamine users: Cross-sectional study in Thailand","volume":"9","author":"Lamyai","year":"2019","journal-title":"BMJ Open."},{"key":"B108","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.psychres.2018.02.017","article-title":"Profile of psychiatric symptoms in methamphetamine users in China: Greater risk of psychiatric symptoms with a longer duration of use","volume":"262","author":"Ma","year":"2018","journal-title":"Psychiatry Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.drugpo.2016.10.018","article-title":"Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population","volume":"38","author":"Lappin","year":"2016","journal-title":"Int J Drug Policy."},{"key":"B110","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.drugalcdep.2018.03.023","article-title":"Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study","volume":"187","author":"Ma","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B111","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0025-7125(16)37027-4","article-title":"Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment","volume":"22","author":"Young","year":"1938","journal-title":"Med Clin North Am."},{"key":"B112","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/bmj.1.5018.582","article-title":"Amphetamine psychosis","volume":"1","author":"Connell","year":"1957","journal-title":"Br Med J."},{"key":"B113","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00491982","article-title":"Amphetamine psychosis and psychotic symptoms","volume":"65","author":"Janowsky","year":"1979","journal-title":"Psychopharmacology (Berl)."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJM197912133012403","article-title":"Development of psychiatric illness in drug abusers","volume":"301","author":"McLellan","year":"1979","journal-title":"N Engl J Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/schbul\/18.1.115","article-title":"Relapse of paranoid psychotic state in methamphetamine model of schizophrenia","volume":"18","author":"Sato","year":"1992","journal-title":"Schizophr Bull."},{"key":"B116","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1176\/ajp.153.6.812","article-title":"When does amphetamine-induced psychosis become schizophrenia?","volume":"153","author":"Flaum","year":"1996","journal-title":"Am J Psychiatry."},{"key":"B117","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/10826084.2018.1521430","article-title":"A systematic review of the symptom profile and course of methamphetamine-associated psychosis: substance use and misuse","volume":"54","author":"Voce","year":"2019","journal-title":"Subst Use Misuse."},{"key":"B118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.comppsych.2019.06.002","article-title":"Is there a discrete negative symptom syndrome in people who use methamphetamine?","volume":"93","author":"Voce","year":"2019","journal-title":"Compr Psychiatry."},{"key":"B119","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fpsyt.2018.00491","article-title":"A comparison of methamphetamine-induced psychosis and schizophrenia: A review of positive, negative, cognitive symptomatology","volume":"9","author":"Wearne","year":"2018","journal-title":"Front Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S0033291703008353","article-title":"Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis","volume":"33","author":"Chen","year":"2003","journal-title":"Psychol Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1600-0447.1994.tb01541.x","article-title":"Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: A preliminary report","volume":"89","author":"Iwanami","year":"1994","journal-title":"Acta Psychiatr Scand."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/NMD.0000000000000059","article-title":"Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment","volume":"201","author":"Lecomte","year":"2013","journal-title":"J Nerv Ment Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.psychres.2016.02.038","article-title":"Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users","volume":"238","author":"McKetin","year":"2016","journal-title":"Psychiatry Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archpsyc.1982.04290020013003","article-title":"Subtypes of drug abuse with psychosis","volume":"39","author":"Tsuang","year":"1982","journal-title":"Arch Gen Psychiatry."},{"key":"B125","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajmg.b.30187","article-title":"Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis","volume":"136","author":"Chen","year":"2005","journal-title":"Am J Med Genet Neuropsychiatr Genet"},{"key":"B126","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1192\/bjp.100.418.29","article-title":"Schizophrenia; a new approach. II. Result of a year's research","volume":"100","author":"Hoffer","year":"1954","journal-title":"J Ment Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","article-title":"Phenomenology, structure, and dynamic of psychedelic states","volume":"36","author":"Preller","year":"2018","journal-title":"Curr Top Behav Neurosci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/2045125316689030","article-title":"Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies","volume":"7","author":"Dos Santos","year":"2017","journal-title":"Ther Adv Psychopharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen dom and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur J Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archpsyc.1966.01730150001001","article-title":"Altered states of consciousness","volume":"15","author":"Ludwig","year":"1966","journal-title":"Arch Gen Psychiatry."},{"key":"B132","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B134","doi-asserted-by":"publisher","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PLoS ONE."},{"key":"B135","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology."},{"key":"B136","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens identification of a new therapeutic class: Entactogens","volume":"18","author":"Nichols","year":"1986","journal-title":"J Psychoactive Drugs."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1360-0443.2006.01511.x","article-title":"The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents","volume":"101","author":"Freudenmann","year":"2006","journal-title":"Addiction."},{"key":"B138","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.2001.10400568","article-title":"An exploration of the history and controversies surrounding mdma and mda","volume":"33","author":"Pentney","year":"2001","journal-title":"J Psychoactive Drugs."},{"key":"B139","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/hup.350","article-title":"Psychiatric disorders in Ecstasy (MDMA) users: A literature review focusing on personal predisposition and drug history","volume":"16","author":"Soar","year":"2001","journal-title":"Hum Psychopharmacol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000059383","article-title":"Ecstasy-induced psychotic disorder","volume":"8","author":"Landabaso","year":"2002","journal-title":"Eur Addict Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/ijerph9072283","article-title":"Symptomatological features of patients with and without Ecstasy use during their first psychotic episode","volume":"9","author":"Rugani","year":"2012","journal-title":"Int J Environ Res Public Health."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.3058","article-title":"Persistent psychosis due to single dose of ecstasy","volume":"10","author":"Virani","year":"2018","journal-title":"Cureus."},{"key":"B143","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0378-4274(99)00219-2","article-title":"Long term psychiatric and cognitive effects of MDMA use","author":"McGuire","year":"2000","journal-title":"Toxicol Lett"},{"key":"B144","first-page":"40","article-title":"Persistent psychosis and medical complications after a single ingestion of MDMA \u201cecstasy\u201d - A case report and review of the literature","volume":"6","author":"Potash","year":"2009","journal-title":"Psychiatry."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.euroneuro.2014.05.008","article-title":"Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases","volume":"24","author":"Litjens","year":"2014","journal-title":"Eur Neuropsychopharmacol."},{"key":"B146","first-page":"396","article-title":"Properties of pentazocine as a discriminative stimulus in the squirrel monkey","volume":"223","author":"White","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"B147","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5607\/en.2017.26.1.11","article-title":"Drug abuse and psychosis: new insights into drug-induced psychosis","volume":"26","author":"Ham","year":"2017","journal-title":"Exp Neurobiol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol Psychiatry."},{"key":"B149","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/JAN.0000000000000060","article-title":"Ketamine users have high rates of psychosis and\/or depression","volume":"26","author":"Liang","year":"2015","journal-title":"J Addict Nurs."},{"key":"B150","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-2007-979354","article-title":"The NMDA antagonist model for schizophrenia: promise and pitfalls","volume":"2","author":"Abi-Saab","year":"1998","journal-title":"Pharmacopsychiatry."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.npp.1300252","article-title":"Altered NMDA glutamate receptorantagonist response in recovering ethanol-dependent patients","volume":"28","author":"Krystal","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"B152","doi-asserted-by":"publisher","first-page":"pyv040","DOI":"10.1093\/ijnp\/pyv040","article-title":"Ketamine-induced modulationof the thalamo-cortical network in healthy volunteers as a model for schizophrenia","volume":"18","author":"H\u00f6flich","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/mp.2012.194","article-title":"Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans","volume":"18","author":"Driesen","year":"2013","journal-title":"Mol Psychiatry"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.neuroimage.2010.08.021","article-title":"Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency","volume":"54","author":"Nagels","year":"2011","journal-title":"NeuroImage."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B156","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs."},{"key":"B157","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/biom10060947","article-title":"Brain NMDA receptors in schizophrenia and depression","volume":"10","author":"Adell","year":"2020","journal-title":"Biomolecules."},{"key":"B158","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00127-008-0490-2","article-title":"First-episode drug-induced psychosis: A medium term follow up study reveals a high-risk group","volume":"44","author":"Crebbin","year":"2009","journal-title":"Soc Psychiatry Psychiatr Epidemiol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.694863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T03:12:30Z","timestamp":1640229150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.694863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":158,"alternative-id":["10.3389\/fpsyt.2021.694863"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.694863","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"694863"}}